|
|
 |
|
Viewing report
|
|
|
|
Biomed Outsourcing Report: Competitive Outsourcing Opportunities-China vs. India
CanBiotech, Sep 2006
This issue comparative analyzes the life sciences industry and outsourcing opportunities in China and India.
The Life Sciences Industry in China article discusses specific developments in China from changes in the R&D paradigm in China to changes in the healthcare system enabling the development of the biopharmaceutical industry. Specific sectors discussed include: biologics, pharmaceuticals, bioservices, and chemicals.
The Outlook on India article discusses the market size, growth anticipated, therapeutic area targets, the top ten companies in India, and the current outlook in India.
A Supportive Environment for Outsourcing to China provides an overview of the impact of strong government support, an emerging middle class, low R&D costs, the availability of talented, low-cost human capital and other special resources on the biotechnology, pharmaceutical and outsourcing sectors.
Outsourcing to India analyzes the impact of India’s cost advantage, research infrastructure, the clinical market and growth on outsourcing opportunities for both
Western companies and Indian service providers.
Challenges to Overcome extends the discussion to intellectual property protection, the need for a strong capital market, better regulatory compliance, and the management of language barriers in China.
Policy Changes Required to Enable Outsourcing in India discusses how rigid administrative price controls, higher import tariffs and tax, and India's patent law are considered to be the main barriers for the Indian pharmaceutical industry.
Business Models Operating in China and India compares various business models including partnerships, mergers and acquisitions, joint ventures, and relocation with outsourcing relationships.
Various company case studies have also been chosen to demonstrate the opportunities available in China and India and how multinational companies, emerging companies, and contract research organizations are taking advantage of these opportunities.
Cases include:
MNCs: AstraZeneca China and India, Eli Lilly China and India, Pfizer China and
India, Quintiles Asia, Quintiles India.
CROs: Bridge Pharmaceuticals Inc., Shanghai Genomics Inc., Starvax Inc., Wuxi Pharma Tech Co. Ltd., Biocon India Group, Syngene, Clinigene, Matrix Laboratories, Siro Clinphama.
|
|
|
|
